1 / 8

Diabetic Ketoacidosis and Complete Remission in Adolescents Post Hematopoietic Stem Cell Transplant

This study evaluates the effectiveness of autologous non-myeloablative hematopoietic stem cell transplantation (AHSCT) for adolescents with type 1 diabetes experiencing diabetic ketoacidosis (DKA) at diagnosis. Enrolling 28 patients aged 14–30, the trial measured changes in insulin requirements and levels of HbA1c, C-peptide, and anti-glutamic acid decarboxylase antibody before and after AHSCT. Results indicate that AHSCT may offer significant benefits, particularly in patients without DKA at diagnosis, leading to long-term insulin independence.

mika
Télécharger la présentation

Diabetic Ketoacidosis and Complete Remission in Adolescents Post Hematopoietic Stem Cell Transplant

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Diabetic Ketoacidosis at Diagnosis Influences Complete Remission After Treatment With Hematopoietic Stem Cell Transplantation in Adolescents With Type 1 Diabetes Weiqiong Gu, M.D., Jiong Hu, M.D., Ph.D., Weiqing Wang, M.D., Lirong Li, M.D., Wei Tang, M.D., Shouyue Sun, M.D., Weijuan Cui, M.D., Lei Ye, M.D., Ph.D, Yifei Zhang, M.D., Ph.D., Jie Hong, M.D., Ph.D., Dalong Zhu, M.D., Guang Ning, M.D., Ph.D. Diabetes Care Volume 35: 1413-1419 July, 2012

  2. Study Objectives • To determine whether autologous nonmyeloablative hematopoietic stem cell transplantation (AHSCT) was beneficial for type 1 diabetic adolescents with diabetic ketoacidosis (DKA) at diagnosis Gu W et al. Diabetes Care 2012;35:1413-1419

  3. Study Design • Enrolled 28 patients with type 1 diabetes, aged 14–30 years, in a prospective AHSCT phase II clinical trial • HSCs harvested from peripheral blood after pretreatment consisting of cyclophosphamide and antithymocyte globulin • Changes in the exogenous insulin requirement and serum levels of HbA1c, C-peptide, and anti-glutamic acid decarboxylase antibody measured before and after the AHSCT Gu W et al. Diabetes Care 2012;35:1413-1419

  4. Gu W et al. Diabetes Care 2012;35:1413-1419

  5. Gu W et al. Diabetes Care 2012;35:1413-1419

  6. Gu W et al. Diabetes Care 2012;35:1413-1419

  7. Gu W et al. Diabetes Care 2012;35:1413-1419

  8. Conclusions • AHSCT appears to be an effective long-term treatment for insulin dependence that achieved a greater efficacy in patients without DKA at diagnosis Gu W et al. Diabetes Care 2012;35:1413-1419

More Related